BNGO Stock Chart & Stats
$69.35
$0.00(0.00%)
At close: 4:00 PM EDT
$69.35
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$69.35 - $69.35
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$268.54M
Enterprise Value$9.33
Total Cash (Recent Filing)$9.92M
Total Debt (Recent Filing)$6.70M
Price to Earnings (P/E)―
Beta-0.15
Next Earnings
Oct 29, 2026EPS Estimate
-7.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.73
Shares Outstanding11,777,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.19
Price to Sales (P/S)0.29
P/FCF Ratio-0.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$68.58Price Target Upside-1.11% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-36.51
Revenue Forecast (FY)$550.81M
Bulls Say, Bears Say
Bulls Say
Recurring Consumable AdoptionRapid growth in flow-cell demand and utilization at existing sites strengthens the recurring-consumables model, which can generate revenue beyond episodic instrument sales. A growing installed base and higher clinical usage may improve customer retention and support more predictable revenue over the next several quarters.
Improving Gross MarginsThe sharp improvement in gross margin indicates better economics as the business shifts toward consumables and increases scale. If sustained, stronger margins can reduce the amount of revenue needed to support operations, improve operating leverage, and help narrow losses as adoption expands.
Clinical And Reimbursement TractionClinical evidence showing OGM can identify relevant abnormalities missed by traditional methods supports its value proposition in diagnostic workflows. CPT coding and progress toward Medicare coverage could improve reimbursement visibility and provide a durable foundation for broader clinical adoption.
Bears Say
Persistent Cash ConsumptionNegative operating and free cash flow mean the company is not yet self-funding despite improved burn rates. Continued cash consumption can restrict investment in commercial expansion and leave liquidity dependent on further cost reductions or access to external capital.
Deep Ongoing LossesThe scale and persistence of net losses show that revenue growth and gross-margin gains have not yet translated into economic profitability. Until operating expenses are brought into balance with gross profit, the business remains exposed to funding needs and execution risk.
Manufacturing Capacity ConstraintsCapacity constraints can prevent the company from converting customer demand into near-term sales, weakening the pace of revenue realization even when adoption is healthy. Persistent backorders may also delay customer workflows and limit the benefits of the expanding installed base.
BioNano Genomics News
BNGO FAQ
What was BioNano Genomics Inc’s price range in the past 12 months?
BioNano Genomics Inc lowest stock price was $69.35 and its highest was $69.35 in the past 12 months.
What is BioNano Genomics Inc’s market cap?
BioNano Genomics Inc’s market cap is $268.54M.
When is BioNano Genomics Inc’s upcoming earnings report date?
BioNano Genomics Inc’s upcoming earnings report date is Oct 29, 2026 which is in 43 days.
How were BioNano Genomics Inc’s earnings last quarter?
BioNano Genomics Inc released its earnings results on Aug 10, 2026. The company reported -$11.315 earnings per share for the quarter, beating the consensus estimate of -$11.487 by $0.171.
Is BioNano Genomics Inc overvalued?
According to Wall Street analysts BioNano Genomics Inc’s price is currently Overvalued.
Does BioNano Genomics Inc pay dividends?
BioNano Genomics Inc does not currently pay dividends.
What is BioNano Genomics Inc’s EPS estimate?
BioNano Genomics Inc’s EPS estimate is -7.71.
How many shares outstanding does BioNano Genomics Inc have?
BioNano Genomics Inc has 11,777,000 shares outstanding.
What happened to BioNano Genomics Inc’s price movement after its last earnings report?
BioNano Genomics Inc reported an EPS of -$11.315 in its last earnings report, beating expectations of -$11.487. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioNano Genomics Inc?
Currently, no hedge funds are holding shares in MX:BNGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioNano Genomics Inc
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
BNGO Company Deck
BNGO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong execution on key commercial and clinical fronts: double-digit revenue growth, record flow-cell sales, a shift to higher-margin consumable revenue, improved gross margins (53%), significant clinical publications validating OGM, and the retirement of convertible debt. These positives were tempered by operational constraints — notably manufacturing capacity and backorders — a modest cash balance with runway into early 2027, and a YoY decline in software revenue. Management raised the low end of full-year guidance but remained cautious on the upside until supply constraints are resolved.View all MX:BNGO earnings summariesBNGO Stock 12 Month Forecast
Average Price Target
$68.58
▼(-1.11% Downside)